We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
Read MoreHide Full Article
Key Takeaways
Spyre saw SPY072 improve DAS28-CRP in RA, with the low dose showing the largest reduction.
SPY072 maintained complete free TL1A suppression through week 12, with a well-tolerated safety profile.
Spyre shifts SPY072 toward broader autoimmune indications after RA monotherapy missed its internal threshold.
Spyre Therapeutics (SYRE - Free Report) announced top-line data from the rheumatoid arthritis (RA) sub-study of its phase II SKYWAY basket study evaluating SPY072, an investigational long-acting anti-TL1A antibody.
The randomized, placebo-controlled SKYWAY-RA study evaluated two doses (high and low) of SPY072 in patients with moderately to severely active RA who had an inadequate response to conventional or advanced therapies. The primary endpoint was the change from baseline in Disease Activity Score in 28 joints, C-reactive protein (DAS28-CRP) at week 12, while ACR20 response at week 12 was a key secondary endpoint.
Key Highlights of SYRE’s Phase II SKYWAY-RA Study
The SKYWAY-RA study data highlighted SPY072’s encouraging activity in RA across both doses. At week 12, the low dose achieved a statistically significant improvement in DAS28-CRP from baseline, with a reduction of 1.9 points compared with 1.3 points for placebo. The high dose produced a 1.5-point reduction. ACR20 and ACR50 responses were numerically higher, at the high and low doses of SPY072, respectively.
Both doses achieved the targeted drug concentrations and maintained complete suppression of free TL1A through week 12, confirming robust target engagement. The treatment was generally well-tolerated, and the safety profile was consistent with the TL1A class.
Spyre Shifts Focus Away From RA Monotherapy
Despite demonstrating proof-of-mechanism for TL1A inhibition in RA, the magnitude of benefit did not meet Spyre’s internal threshold to advance SPY072 as an RA monotherapy, which investors interpreted as a setback for the program. Consequently, the company is shifting its development focus toward broader autoimmune indications and combination therapies.
The update likely disappointed investors, with Spyre shares falling nearly 4% in after-hours trading on Tuesday.
Year to date, Spyre’s shares have skyrocketed 227.8% compared with the industry’s 10.8% growth.
Image Source: Zacks Investment Research
More on Spyre’s SPY072
The SKYWAY basket study is evaluating SPY072 across three rheumatic diseases: RA, psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). In June, Spyre completed enrollment in PsA and axSpA sub-studies. The company expects to report top-line proof-of-concept data from both studies in the fourth quarter of 2026.
Earlier this month, Spyre expanded its development strategy into hidradenitis suppurativa (HS), evaluating a long-acting combination of SPY072 and SPY007 (anti-IL-17A/F). The combination will be evaluated in the phase II SKYLIGHT proof-of-concept study, with top-line data expected in late 2027 or early 2028.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.00 to $1.02 for 2026. Over the same period, estimates for earnings per share increased from $1.12 to $1.21 for 2027. AMRX shares have risen 42.2% year to date.
Amneal Pharmaceuticals beat earnings in each of the trailing four quarters, delivering an average surprise of 32.82%.
Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have declined 7% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
Over the past 30 days, estimates for Precigen’s 2026 loss per share have improved from a loss of two cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have gained 74.2% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
View the Zacks #1 Rank List
Image: Bigstock
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
Key Takeaways
Spyre Therapeutics (SYRE - Free Report) announced top-line data from the rheumatoid arthritis (RA) sub-study of its phase II SKYWAY basket study evaluating SPY072, an investigational long-acting anti-TL1A antibody.
The randomized, placebo-controlled SKYWAY-RA study evaluated two doses (high and low) of SPY072 in patients with moderately to severely active RA who had an inadequate response to conventional or advanced therapies. The primary endpoint was the change from baseline in Disease Activity Score in 28 joints, C-reactive protein (DAS28-CRP) at week 12, while ACR20 response at week 12 was a key secondary endpoint.
Key Highlights of SYRE’s Phase II SKYWAY-RA Study
The SKYWAY-RA study data highlighted SPY072’s encouraging activity in RA across both doses. At week 12, the low dose achieved a statistically significant improvement in DAS28-CRP from baseline, with a reduction of 1.9 points compared with 1.3 points for placebo. The high dose produced a 1.5-point reduction. ACR20 and ACR50 responses were numerically higher, at the high and low doses of SPY072, respectively.
Both doses achieved the targeted drug concentrations and maintained complete suppression of free TL1A through week 12, confirming robust target engagement. The treatment was generally well-tolerated, and the safety profile was consistent with the TL1A class.
Spyre Shifts Focus Away From RA Monotherapy
Despite demonstrating proof-of-mechanism for TL1A inhibition in RA, the magnitude of benefit did not meet Spyre’s internal threshold to advance SPY072 as an RA monotherapy, which investors interpreted as a setback for the program. Consequently, the company is shifting its development focus toward broader autoimmune indications and combination therapies.
The update likely disappointed investors, with Spyre shares falling nearly 4% in after-hours trading on Tuesday.
Year to date, Spyre’s shares have skyrocketed 227.8% compared with the industry’s 10.8% growth.
Image Source: Zacks Investment Research
More on Spyre’s SPY072
The SKYWAY basket study is evaluating SPY072 across three rheumatic diseases: RA, psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). In June, Spyre completed enrollment in PsA and axSpA sub-studies. The company expects to report top-line proof-of-concept data from both studies in the fourth quarter of 2026.
Earlier this month, Spyre expanded its development strategy into hidradenitis suppurativa (HS), evaluating a long-acting combination of SPY072 and SPY007 (anti-IL-17A/F). The combination will be evaluated in the phase II SKYLIGHT proof-of-concept study, with top-line data expected in late 2027 or early 2028.
SYRE’s Zacks Rank & Stocks to Consider
Spyre currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals (AMRX - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), while AC Immune (ACIU - Free Report) and Precigen (PGEN - Free Report) carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.00 to $1.02 for 2026. Over the same period, estimates for earnings per share increased from $1.12 to $1.21 for 2027. AMRX shares have risen 42.2% year to date.
Amneal Pharmaceuticals beat earnings in each of the trailing four quarters, delivering an average surprise of 32.82%.
Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have declined 7% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
Over the past 30 days, estimates for Precigen’s 2026 loss per share have improved from a loss of two cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have gained 74.2% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.